/Pfizer%20Inc_%20logo%20on%20iPad-by%20Koshiro%20K%20via%20Shutterstock.jpg)
Pfizer (PFE) is a pharmaceutical and biotechnology company valued at $145 billion by market capitalization. While the company is more recently renowned for its COVID-19 vaccine, it also develops medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.
Despite a positive fourth-quarter report that beat consensus estimates, Pfizer stock is down 3.2% year-to-date, compared to the S&P 500 Index’s ($SPX) gain of 4.2%. Let’s find out if Pfizer stock is a good buy now.